New antihemorrhagic agents: a novel antifibrinolytic strategy

• Hemorrhage is a leading cause of death and cost associated with blood transfusion.

• There is a need for the improvement of current treatments of bleeding associated with  surgery, trauma, intracerebral hemorrhage (ICH) or other tissue damages.

• A novel target involved in fibrinolysis has been identified.

• Proprietary novel compounds to prevent major bleeding have been developed:

  • Small molecule entity (SME).

  • Efficacy: 30,000 times more effective than the currently available therapies.

  • Safety: No thrombus formation and no impact on coagulation.

• Primary Indication: prophylaxis and acute treatment of bleeding in cardiac surgery.

>> Download information